Advertisement

Clinical & Experimental Metastasis

, Volume 34, Issue 8, pp 479–490 | Cite as

Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases

  • Mariz Kasoha
  • Clara Unger
  • Erich-Franz Solomayer
  • Rainer M. Bohle
  • Claudia Zaharia
  • Fadi Khreich
  • Stefan Wagenpfeil
  • Ingolf Juhasz-Böss
Research Paper

Abstract

The present study was undertaken to investigate the expression of prostate-specific membrane antigen (PSMA) in normal breast tissues, in cancerous breast tissues and in distant metastases from patients with breast cancer. Immunohistochemical analysis was performed to determine PSMA expression and angiogenic activity using anti-PSMA mAb and anti-CD31 mAb respectively. Immunofluorescence staining was applied to confirm the exact co-localization of PSMA and CD31. We observed different patterns of PSMA expression between normal and cancerous tissues. Normal breast tissues showed PSMA expression only in normal glandular cells. However, primary breast tumors and distant metastases showed PSMA expression in tumor cells and in tumor-associated neovasculature. PSMA score group status in primary breast tumors was significantly associated with histologic type and tumor grade (p = 0.026 and p = 0.004 respectively). Distant metastases showed higher PSMA expression in tumor-associated neovasculature comparing with primary tumors. Moreover, brain tumor-associated neovasculture had significantly higher expression of PSMA comparing with bone tumor-associated neovasculture. The localized binding of PSMA mAb to the neovasculature endothelium was confirmed with the double Immunofluorescence staining. 68Ga-PSAM imaging of a patient with metastatic breast cancer showed strong tracer uptake in all known skeletal metastases. To the best of our knowledge, this study is the second one that has assessed PSMA expression in a large number of breast cancer patients. Our findings showed that PSMA is particularly expressed in tumor-associated neovasculature of breast tumors and its distant metastases, thus enhancing the evidence on the potential usefulness of PSMA as a therapeutic vascular target.

Keywords

Breast cancer Prostate-specific membrane antigen (PSMA) Angiogenesis Metastases Neovasculature 

Notes

Acknowledgements

We thank Barbara Linxweiler from the department of obstetrics and gynecology, University Medical School of Saarland for her excellent technical assistance.

References

  1. 1.
    Israeli RS, Powell CT, Fair WR, Heston WD (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53: 227–230PubMedGoogle Scholar
  2. 2.
    Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85PubMedGoogle Scholar
  3. 3.
    Godron IO, Tretiakova MS, Noffsinger AE, Hart J, Reuter VE, Al-Ahmadie HA (2008) Prostate-specific membrane antigen expression in regeneration and repair. Mod Pathol 21:1421–1427CrossRefGoogle Scholar
  4. 4.
    Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Peter M, Rovito PM Jr, Wang CY, Haas GP (2006) Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 30(4): 628–636CrossRefPubMedGoogle Scholar
  5. 5.
    Rajasekaran AK, Anilkumar G, Christiansen JJ (2005) Is prostate-specific membrane antigene a multifunctional protein? Am J Physiol Cell Cell Physiol 288: C975–C981CrossRefGoogle Scholar
  6. 6.
    Shafizadeh TB, Halsted CH (2007) Gamma-glutamyl hydrolase, not glutamate carboxypeptidase II, hydrolyzes dietary folate in rat small intestine. J Nutr 137:1149–1153CrossRefPubMedGoogle Scholar
  7. 7.
    Neale JH, Bzdega T, Wroblewska B (2000) N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J Neurochem 75(2):443–452CrossRefPubMedGoogle Scholar
  8. 8.
    Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696–670CrossRefPubMedGoogle Scholar
  9. 9.
    Ghosh A, Heston WD (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528–539CrossRefPubMedGoogle Scholar
  10. 10.
    Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH (2003) Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 170:S84–S88CrossRefPubMedGoogle Scholar
  11. 11.
    Troyer JK, Beckett ML, Wright GL Jr (1995) Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62:552–558CrossRefPubMedGoogle Scholar
  12. 12.
    Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, Bander NH, Rajasekaran AK (2003) A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell 14:4835–4845CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Pfestroff A, Luster M, Jilg CA, Olbert PJ, Ohlmann CH, Lassmann M, Maecke HR, Ezziddin S, Bodei L (2015) Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks. Eur J Nucl Med Mol Imaging 42:1971–1975CrossRefPubMedGoogle Scholar
  14. 14.
    Osborna JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST (2013) Prostate-specific membrane antigen-based imaging. Urol Oncol 31:144–154CrossRefGoogle Scholar
  15. 15.
    Jadvar H (2015) PSMA PET in prostate cancer. J Nucl Med 56:1131–1132CrossRefPubMedGoogle Scholar
  16. 16.
    Ceci F, Uprimny C, Nilica B et al (2015) (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 42:1284–1294CrossRefPubMedGoogle Scholar
  17. 17.
    Scott T, Tagawa MI, Milowsky M, Morris S, Vallabhajosula P, Christos NH, Akhtar et al (2013) Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 19:5182–5191CrossRefGoogle Scholar
  18. 18.
    Weineisen M, Schottelius M, Simecek J et al (2015) 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 56:1169–1176CrossRefPubMedGoogle Scholar
  19. 19.
    Ren H, Zhang H, Wang X, Liu J, Yuan Z, Hao J (2014) Prostate-specific membrane antigen as a marker of pancreatic cancer cells. Med Oncol 31(3):857CrossRefPubMedGoogle Scholar
  20. 20.
    Wang HL, Wang SS, Song WH, Pan Y, Yu HP, Si TG, Liu Y, Cui XN, Gue Z (2015) Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS ONE.  https://doi.org/10.1371/journal.pone.0125924 Google Scholar
  21. 21.
    Haffner MC, Kronberger IE, Ross JS et al (2009) Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 40:1754–1761CrossRefPubMedGoogle Scholar
  22. 22.
    Baccala A, Sercia L, Li J, Heston W, Zhou M (2007) Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 70:385–390CrossRefPubMedGoogle Scholar
  23. 23.
    Samplaski MK, Heston W, Elson P, Magi-Galluzzi C, Hansel DE (2011) Folate hydrolase (prostate-specific membrane antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Mod Pathol 24:1521–1529CrossRefPubMedGoogle Scholar
  24. 24.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer inciedence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:359–386CrossRefGoogle Scholar
  25. 25.
    Wernicke AG, Varma S, Greenwood EA, Christos EA, Chao PJ, Liu KS, Bander H, Shin NH SJ (2013) Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. Acta Pathol Microbiol Immunol Scand (APMIS) 122:482–489CrossRefGoogle Scholar
  26. 26.
    Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140PubMedGoogle Scholar
  27. 27.
    Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G (1992) Tumor angiogenesis: a new significant and independent indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875–1887CrossRefPubMedGoogle Scholar
  28. 28.
    Ahmadzadehfar H, Zimbelmann S, Yordanova, A, Fimmers R, Kürpig S, Eppard E, Gaertner FC, Wei X, Hauser S, Essler M (2017) Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride. Oncotarget.  https://doi.org/10.18632/oncotarget.15698 Google Scholar
  29. 29.
    Uwe Haberkorn M, Eder K, Kopka JW, Babich, Eisenhut M (2017) New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clin Cancer Res.  https://doi.org/10.1158/1078-0432.CCR-15-0820 PubMedGoogle Scholar
  30. 30.
    Nomura N, Pastorino S, Jiang P, Lambert G, Crawford JR, Gymnopoulos M, Piccioni D, Juarez T, Pingle SC, Makale M, Kesari S (2014) Prostate specificmembraneantigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int.  https://doi.org/10.1186/1475-2867-14-26 PubMedPubMedCentralGoogle Scholar
  31. 31.
    Tykvart J, Navrátil V, Sedlák F, Corey E, Colombatti M, Fracasso G, Koukolík F, Bařinka C, Sácha P, Konvalinka J (2014) Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA). Prostate 74:1674–1690CrossRefPubMedGoogle Scholar
  32. 32.
    Chang S, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Prostate 59:3192–3198Google Scholar
  33. 33.
    Mhawech-Fauceglia P, Zhang S, Terracciano L, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R (2007) Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 50:472–483CrossRefPubMedGoogle Scholar
  34. 34.
    Ross JS, Schenkein D, Webb I, Gray G, Deeds J, Meyer R, McDonald A, Sheehan C, Gray K (2004) Expression of prostate specific membrane antigen in the neo-vasculature of non-prostate cancers. J Clin Oncol 22(14-suppl):3110CrossRefGoogle Scholar
  35. 35.
    Bradbury R, Jiang WG, Cui YX (2016) MDM2 and PSMA play inhibitory roles in metastatic breast cancer cells through regulation of matrix metalloproteinases. Anticancer Res 36:1143–1152PubMedGoogle Scholar
  36. 36.
    Liu T, Jabbes M, Nedrow-Byers JR, Wu LY, Bryan JN, Berkman CE (2011) Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium. Int J Oncol 38:1349–1355PubMedGoogle Scholar
  37. 37.
    Nguyen DP, Xiong PL, Liu H, Pan S, Leconet W, Navarro V et al (2016) Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment. Mol Cancer Res 14:1045–1053CrossRefPubMedGoogle Scholar
  38. 38.
    Al-Ahmadie HA, Olgac S, Gregor PD, Tickoo SK, Fine SW, Kondagunta GV, Scher HI, Morris MJ, Russo P, Motzer RJ, Reuter VE (2008) Expression of prostate-specific membrane antigen in renal cortical tumors. Mod Pathol 21:727–732CrossRefPubMedGoogle Scholar
  39. 39.
    Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH (2006) Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 26:5310–5324CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Evans JC, Malhorta M, Cryan JF, OʹDriscoll CM (2016) The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. Br J Pharmacol 173:3041–3079CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Sathekge M, Modiselle M, Vorster M, Mokgoro N, Nyakale N, Mokaleng B, Ebenhan T (2015) 68Ga-PSMA imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging 42:1482–1483CrossRefPubMedGoogle Scholar
  42. 42.
    Sathekge M, Lengana T, Modiselle M, Vorster M, Zeevaat JR, Maes A, Ebenhan T, Van de Wiele C (2017) 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging 44:689–694CrossRefPubMedGoogle Scholar
  43. 43.
    Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM et al (2016) Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clin Cancer Res 22:3157–3163CrossRefGoogle Scholar
  44. 44.
    Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH (2007) Vascular targeted therapy with anti-prostate specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 25:540–547CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  • Mariz Kasoha
    • 1
  • Clara Unger
    • 1
  • Erich-Franz Solomayer
    • 1
  • Rainer M. Bohle
    • 2
  • Claudia Zaharia
    • 2
  • Fadi Khreich
    • 3
  • Stefan Wagenpfeil
    • 4
  • Ingolf Juhasz-Böss
    • 1
  1. 1.Department of Gynecology, Obstetrics and Reproductive MedicineUniversity Medical School of SaarlandHomburgGermany
  2. 2.Institute of General and Surgical PathologyUniversity Medical School of SaarlandHomburgGermany
  3. 3.Department of Nuclear MedicineSaarland UniversityHomburgGermany
  4. 4.Institute of Medical Biometry, Epidemiology and Medical InformaticsSaarland UniversityHomburgGermany

Personalised recommendations